UMATROPE 12 mg/3 ml, powder and solvent for solution for injection cartridge, 3.15 ml
Active ingredients: Growth hormone
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for solution for injectioncartridge, 3.15 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- UMATROPE 12 mg/3 mL, poudre et solvant pour solution injectable
- Pharmaceutical form
- poudre et solvant pour solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 cartouche(s) en verre - 1 seringue(s) préremplie(s) de 3,15 ml
- Marketing authorisation holder
- LILLY FRANCE
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 1 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65675287CIP73421593CIP133400934215933Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SOMATROPINEpoudre | 12 mg · une cartouche | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.